Chung Han Yang

Main interest: Mental health, HIV, public health intervention & policy. Currently working on Hep C Access & Advocacy with @DNDi. Passionate on food history!

[Drugs for Neglected Diseases initiative @DNDi]

#JobOpening in Malaysia! 🇲🇾 We're hiring a South-East Asia Director to manage our activities in the region, lead strategic development and collaborations & mobilize governments and other stakeholders.

Apply or help us share! 👉 https://t.co/Sk9mKGDICE #ngojob #globalhealthjob

[Drugs for Neglected Diseases initiative @DNDi]

Hepatitis C is a public health concern affecting 58 million people worldwide. At #MSFSciAsia, @DrRosaida spoke about the impact of #hepatitisC on healthcare systems & the decentralisation journey in Malaysia, a project in partnership with @KKMPutrajaya @ClinicalRsrchMY & @FINDdx.

[Hep Drug Interactions @hepinteractions]

💊 New Direct Acting Antiviral added to the hepatology drug interaction checker: Ravidasvir (Ravida®). Ravidasvir is an NS5A inhibitor approved for use with sofosbuvir, which provides an affordable cure for low-middle income countries. Many thanks to @DNDi for their help.

[Drugs for Neglected Diseases initiative @DNDi]

What would the development of a dengue treatment mean for people living with #dengue?

@JMP_DNDi was interviewed by @melisa_idris on @501awani where he spoke about the need for international cooperation to tackle this climate-sensitive disease. #beatNTDs https://t.co/Pygltke8Gk

[Chung Han Yang @ChungHanYang2]

@AnushiyaKaruna1 @SemXiaohui Great to work together on this important meeting with the community!

[Chung Han Yang @ChungHanYang2]

@DNDi @MSF_SouthAsia @TAGTeam_Tweets @FINDdx #HepatitisCPACT is proud to partner with @IRDGlobal to support DGHS MOHFW #Bangladesh on pioneering pragmatic strategy #Hepatitis elimination.
Great public leadership from 🇧🇩 to bring more 💊💉for #HCV #HBV in coming years! @JMP_DNDi

[Chung Han Yang @ChungHanYang2]

Great conclusion of #CRMTrialConnect2023 by DG @radzi_dr: Clinical trials need to be patient centric, bringing impact to patient care like in 🇲🇾 experience in #hepatitisC trials

Amazing passion on R&D with our partners
@ClinicalRsrchMY @DNDi @ICR_NIH

[Aiezat Fadzell @AiezatFadzell]

Appreciate the visit, @Khairykj , to @DNDi booth at #CRMTrialConnect2023! Productive talks on expanding Dengue portfolio in 🇲🇾 & the significance of point-of-care testing for patients. Collaboration for improved healthcare continues!

@JMP_DNDi @TilakbabuR @ClinicalRsrchMY

[Chung Han Yang @ChungHanYang2]

#HCV Elimination need to continue despite COVID, reaching the hard to reach (prison, refugees, MSM etc) through innovation, partnership & integration.

Great week at #ISIDCongress2022 🇲🇾speaking with delegates across the world
@ISID_org @DrRosaida @SemXiaohui
@DNDi @FINDdx

[Xiaohui Sem @SemXiaohui]

photo credit: @ChungHanYang2

[Chung Han Yang @ChungHanYang2]

Great to see #Ravidasvir progressing into a new milestone today, now recommended as the main choice of DAA for PLHIV in 🇲🇾 thanks to our Storm-C PI & expert @drsstan. Read more on the guideline: https://t.co/KbRVX2rEeU

[Soek-Siam Tan @drsstan]

The 2022 Malaysian ART consensus guideline was launched today at MyHIV FORUM 2022. A comprehensive guide including sections on viral hepatitis. Happy to see our Infectious Disease colleagues recommended #Ravidasvir (RDV) + Sofosbuvir for PLHIVHCV

[Chung Han Yang @ChungHanYang2]

thanks to @SemXiaohui for bringing a copy of the recommendation from #EASL 2022 😆

[Chung Han Yang @ChungHanYang2]

insightful to speak to Dr Anchalee @HIVNAT & @DNDi PI #Ravidasvir. She co-chaired GDG for WHO Updated recommendations on simplified service delivery & diagnostics for #HCV: decentralization, integration & task sharing will be key for #HCV care expansion
https://t.co/gHbAIE8EpW

[Xiaohui Sem @SemXiaohui]

#throwback #EASL ILC 2022 in London 2 mths ago, I presented our work “Randomized controlled trial of home-based hepatitis C self-testing for key populations in Malaysia”.

[Family Frontiers #sayaJUGAanakMalaysia @FamilyFrontiers]

Breaking: The Fight Goes On For Malaysian Women as Court of Appeal Overturns High Court Decision in Suriani Kempe Case.

The Court of Appeal in a 2-1 decision overturns the landmark High Court decision in Suriani Kempe & Ors v Government of Malaysia & Ors.

[Anne James @annejames44]

@FamilyFrontiers

[South China Morning Post @SCMPNews]

Political will needed to end the unnecessary suffering of hepatitis C patients https://t.co/1o4JdNh2sd